Picture of Aptose Biosciences logo

APS — Aptose Biosciences Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-6.87%
3m-35.2%
6m-33.3%
1yr-73.22%
Volume Change (%)
10d/3m-44.45%
Price vs... (%)
52w High-75.48%
50d MA-18.59%
200d MA-46.49%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-92.96%
Return on Equity-69.39%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Aptose Biosciences EPS forecast chart

Profile Summary

Aptose Biosciences Inc. is a Canada-based clinical stage precision oncology biotechnology company. It is engaged in advancing kinase inhibitors to treat unmet medical needs in life-threatening cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndrome (MDS) and other hematologic malignancies. Its HM43239 is being evaluated in an international Phase I/II study in patients with relapsed or refractory AML. Its Luxeptinib is being evaluated in a Phase I a/b trial in patients with relapsed or refractory B cell malignancies, and in a separate Phase I a/b trial in patients with relapsed or refractory AML or high-risk MDS. Its APTO-253 is a small molecule MYC oncogene inhibitor at the Phase Ia/b clinical trial stage of development for the treatment of patients with relapsed or refractory (R/R) blood cancers, including AML and high-risk MDS. Its APL-581 is a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
November 1st, 2006
Public Since
June 4th, 1993
No. of Shareholders
38
No. of Employees
41
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconToronto Stock Exchange
Shares in Issue
92,229,189

APS Share Price Performance

Upcoming Events for APS

Q2 2022 Aptose Biosciences Inc Earnings Release

Q3 2022 Aptose Biosciences Inc Earnings Release

Similar to APS

Picture of AEterna Zentaris logo

AEterna Zentaris

ca flag iconToronto Stock Exchange

Picture of Antibe Therapeutics logo

Antibe Therapeutics

ca flag iconToronto Stock Exchange

Picture of Appili Therapeutics logo

Appili Therapeutics

ca flag iconToronto Stock Exchange

Picture of Avicanna logo

Avicanna

ca flag iconToronto Stock Exchange

Picture of BELLUS Health logo

BELLUS Health

ca flag iconToronto Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email